Gemlapodect

Gemlapodect
Clinical data
Other namesNOE-105; NOE105
Routes of
administration		Oral[1]
Drug classPhosphodiesterase PDE10A inhibitor
Identifiers
  • 1-methyl-4-(morpholine-4-carbonyl)-N-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyrazole-5-carboxamide
CAS Number
PubChem CID
DrugBank
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC22H21N7O3
Molar mass431.456 g·mol−1
3D model (JSmol)
  • CN1C(=C(C=N1)C(=O)N2CCOCC2)C(=O)NC3=CC4=NC(=NN4C=C3)C5=CC=CC=C5
  • InChI=1S/C22H21N7O3/c1-27-19(17(14-23-27)22(31)28-9-11-32-12-10-28)21(30)24-16-7-8-29-18(13-16)25-20(26-29)15-5-3-2-4-6-15/h2-8,13-14H,9-12H2,1H3,(H,24,30)
  • Key:MMCSMWHWVGGCGL-UHFFFAOYSA-N

Gemlapodect (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code name NOE-105) is a phosphodiesterase PDE10A inhibitor which is under development for the treatment of Tourette's syndrome and speech disorders.[1][2][3] It is taken orally.[1] The drug is thought to work by modulating dopaminergic signaling in the striatum through PDE10A inhibition in medium spiny neurons.[3] Gemlapodect was originated by Roche and is under development by Noema Pharma.[1][2] As of September 2025, it is in phase 2 clinical trials for both Tourette's syndrome and speech disorders.[1][2]

See also

References

  1. ^ a b c d e "Noema Pharma". AdisInsight. 18 September 2025. Retrieved 2 June 2026.
  2. ^ a b c "Delving into the Latest Updates on Gemlapodect with Synapse". Synapse. 10 March 2026. Retrieved 2 June 2026.
  3. ^ a b Häge A, Krämer R, Dunlap M, Mechler K, Müller-Vahl KR, Nagy P (June 2025). "Emerging therapeutic approaches for Tourette syndrome and other tic disorders - a systematic review of current clinical trials". European Child & Adolescent Psychiatry. 34 (6): 1719–1729. doi:10.1007/s00787-024-02637-x. PMID 39714607.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.